GlassScriptPhysician profile
Tara K Robertson
NPI 1104204122
$6,061.79
in general payments reported to CMS, 2019-2025
26 companies · $1,286 in 2025
The $1,286 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $885 · 2022: $1,439 · 2023: $1,207 · 2024: $1,245 · 2025: $1,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,297 · Education: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,297.00 |
| Education | $440.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,492.73 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,389.49 | 2021-2025 | |
| Abbvie INC. | $565.00 | 2021-2025 | |
| Incyte Corporation | $392.16 | 2023-2025 | Opzelura |
| Amgen INC. | $273.68 | 2022-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $257.84 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $238.68 | 2021-2024 | Taltz, Olumiant |
| Pfizer INC. | $229.17 | 2021-2025 | |
| Galderma Laboratories, L.P. | $194.89 | 2021-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $188.85 | 2021-2023 | Ilumya |
| Janssen Scientific Affairs, LLC | $124.99 | 2022 | |
| Genzyme Corporation | $119.84 | 2021-2024 | |
| Ucb, INC. | $115.23 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $84.17 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $83.76 | 2021-2024 | Siliq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $64.95 | 2021 | |
| Dermavant Sciences, INC. | $57.81 | 2023-2024 | Vtama |
| Biofrontera INC. | $32.70 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Kerecis Limited | $31.68 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Merz North America, INC. | $24.95 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.01 | 2023 | Dupixent |
| Vyne Pharmaceuticals INC. | $21.21 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.43 | 2023 | Spevigo |
| Otsuka America Pharmaceutical, INC. | $14.29 | 2024 | Abilify Asimtufii, Abilify Maintena |
| Smith+Nephew, INC. | $11.34 | 2021 | |
| Organon LLC | $9.94 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.